Capricor Therapeutics, Inc., a clinical-stage biotechnology company operating within the healthcare sector, has announced its intention to release its second-quarter 2026 financial results following the market close on August 13. The company, which specializes in the development and commercialization of biological therapies for Duchenne muscular dystrophy (DMD) and other rare disorders, will host a conference call and webcast on the same day to discuss the financial outcomes. A replay of this event will be made available to investors shortly thereafter.
Capricor Therapeutics is headquartered in Beverly Hills, United States, and serves markets in both the US and Canada. The company is listed on the Nasdaq stock exchange and trades under the currency of USD. As of August 9, 2026, the close price of Capricor’s stock was $3.85, with a 52-week high of $40.37 recorded on December 2, 2025, and a 52-week low of $2.96 on July 29, 2026. The company’s market capitalization stands at approximately $236.86 million, with a price-to-earnings ratio of -1.81.
The company’s lead candidate, Deramiocel, is a cardiac-derived cell therapy currently in late-stage development for the treatment of Duchenne muscular dystrophy. Additionally, Capricor is advancing its proprietary StealthX platform, which is designed for the targeted delivery of various therapeutic agents.
In a separate development, Kaplan Fox & Kilsheimer LLP has notified investors who acquired Capricor securities between December 2025 and July 2026 of a securities class action filed on their behalf. The deadline for participation in this action is set for September 28, 2026.
For more detailed information about Capricor Therapeutics’ activities and offerings, interested parties are encouraged to visit their website at www.capricor.com .
